A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations

Not yet recruiting

• Conditions: Medullary Thyroid Cancer (MTC)

• Registration Number: NCT07048964
• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Brief Summary

This trial is a prospective, observational Phase II clinical study. For patients with locally advanced and/or metastatic medullary thyroid carcinoma with RET gene mutations who require systemic treatment, they are randomly assigned to either the Pralsetinib or Anlotinib observation cohort based on their clinical treatment choices. The treatment continues until disease progression or the occurrence of intolerable adverse reactions. At the same time, the correlation between the efficacy and safety of the drugs and the RET gene mutation subtypes is analyzed, and the resistance mechanisms of Anlotinib and Pralsetinib are preliminarily explored to provide more evidence for the clinical treatment of patients with locally advanced or metastatic MTC in China.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-05-23
• Status Verified: 2025-06
• Study First Submitted QC: 2025-06-30
• Last Update Submitted: 2025-06-30
• Study First Posted: 2025-07-03
• Last Update Posted: 2025-07-03
• Study Start: 2025-08-01
• Primary Completion: 2026-02-28
• Study Completion: 2027-02-28

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Age ≥18 years.
• Pathologically confirmed medullary thyroid carcinoma (MTC).
• Patients with locally advanced or metastatic MTC who require systemic treatment.
• Disease progression within 14 months before the screening visit.
• Presence of RET gene mutations based on tumor tissue and/or blood evaluations conducted by the study center.
• No prior treatment with pralsetinib and/or anlotinib and/or cabozantinib and/or vandetanib.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
• Expected survival time ≥ 3 months
• Signed informed consent to participate in this study.

Exclusion Criteria

• The patient meets any of the following criteria within 14 days before the first administration of the study drug:

  1. Platelet count < 75 × 10^9/L.
  2. Absolute neutrophil count (ANC) < 1.0 × 10^9/L.
  3. Hemoglobin < 9.0 g/dL, with the possibility of elevating hemoglobin to 9.0 g/dL or higher through red blood cell transfusion and erythropoietin use, provided such treatment is completed at least 2 weeks before the first administration of the study drug.
  4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × upper limit of normal (ULN) without liver metastases; > 5 × ULN with liver metastases.
  5. Total bilirubin > 1.5 × ULN, > 3 × ULN with liver metastases; in the case of Gilbert's syndrome, total bilirubin > 3 × ULN and direct bilirubin > 1.5 × ULN.
  6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance < 60 mL/min.

• The patient's QTcF > 470 msec. The patient has a history of long QT syndrome or torsades de pointes (TdP). The patient has a family history of long QT syndrome.

• The patient has clinically significant, uncontrolled cardiovascular diseases, including congestive heart failure classified as New York Heart Association (NYHA) Class III or IV; myocardial infarction or unstable angina within 6 months; uncontrolled hypertension; or clinically significant uncontrolled arrhythmias, including bradyarrhythmias that may lead to QT prolongation (e.g., second-degree atrioventricular block type II or third-degree atrioventricular block).

• The patient has metastatic central nervous system (CNS) tumors or primary CNS tumors with progressive neurological symptoms or requiring an increased dose of corticosteroids to control CNS disease. If corticosteroid treatment is needed for CNS disease, the dosing must be stable within the two weeks prior to C1D1.

• The patient has symptomatic interstitial lung disease or interstitial pneumonia, including radiation pneumonitis (i.e., affecting daily activities or requiring therapeutic intervention).

• The patient has received anti-tumor therapy within 14 days or five half-lives of the study drug prior to the first administration.

• The patient has received granulocyte colony-stimulating factor (G-CSF) support therapy within 14 days prior to the first administration of the study drug.

• The patient has undergone major surgery (excluding central venous catheterization, tumor biopsy, and gastrostomy tube insertion) within 14 days before the first administration of the study drug.

• The patient has been diagnosed with or requires treatment for another primary malignancy within the past 3 years, except for completely resected basal cell and squamous cell carcinoma of the skin, localized prostate cancer after curative treatment, and any in situ carcinoma that has been fully resected.

• The patient is unwilling or unable to comply with scheduled visits, dosing plan, laboratory tests, or other study procedures and restrictions.

• Non-menopausal or non-surgically sterilized female subjects are unwilling to use abstinence or highly effective contraception during the study drug administration and for at least 30 days after the last administration of the study drug; non-sterilized male subjects are unwilling to use abstinence or highly effective contraception during the study drug administration and for at least 90 days after the last administration of the study drug.

• Female patients who are currently breastfeeding.

• In the investigator's judgment, the patient has previous or current clinically significant conditions, medical history, surgical history, physical examination findings, or laboratory abnormalities that might affect patient safety, alter the absorption, distribution, metabolism, or excretion of the study drug, or interfere with the evaluation of study results.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the objective response rate (ORR) of Pralsetinib or Anlotinib in patients with RET gene mutation-related locally advanced or metastatic medullary thyroid carcinoma (MTC) who require systemic treatment	24 months	Defined as complete response (CR) or partial response (PR) according to RECIST v1.1

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS) as assessed by Investigator	24 months
Conversion rate of initially inoperable locally advanced medullary thyroid carcinoma (MTC) patients to surgically resectable status after treatment with pralsetinib or anlotinib	24 months
Duration of Response (DOR)	24 months	Defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death from any cause, whichever occurs first
Disease control rate (DCR)	24 months
Changes in blood calcitonin (CT) and carcinoembryonic antigen (CEA)	24 months
Safety: Type incidence and severity (as graded by NCI CTCAE v 4.0) of Pralsetinib or Anlotinib	24 months	Seriousness and attribution to the study medications of AEs and any laboratory abnormalities